Halozyme Therapeutics, Inc.

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.In addition to our proprietary product pipeline, Halozyme has value-driving partnerships with leading pharmaceutical companies.

Bank Name Halozyme Therapeutics, Inc.
Stock Exchange NASDAQ
Symbol HALO
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region America
CEO Dr. Helen I. Torley
Employees 255
Website www.halozyme.com
Registered Year 1998